Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 2
2009 1
2016 2
2019 1
2021 2
2022 8
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, Bögemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR. Hussain M, et al. Among authors: verholen f. J Clin Oncol. 2023 Jul 10;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16. J Clin Oncol. 2023. PMID: 36795843 Clinical Trial.
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study.
Rahbar K, Essler M, Pabst KM, Eiber M, Fougère C, Prasad V, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Fendler WP, Kurtinecz M, Schmall A, Verholen F, Sartor O. Rahbar K, et al. Among authors: verholen f. J Nucl Med. 2023 Apr;64(4):574-578. doi: 10.2967/jnumed.122.264456. Epub 2022 Oct 27. J Nucl Med. 2023. PMID: 36302656 Free PMC article.
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR. Saad F, et al. Among authors: verholen f. Eur Urol. 2024 Oct;86(4):329-339. doi: 10.1016/j.eururo.2024.03.036. Epub 2024 Apr 21. Eur Urol. 2024. PMID: 38644146 Free article. Clinical Trial.
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study).
Rahbar K, Essler M, Eiber M, la Fougère C, Prasad V, Fendler WP, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Pabst KM, Kurtinecz M, Schmall A, Verholen F, Sartor O. Rahbar K, et al. Among authors: verholen f. J Nucl Med. 2023 Dec 1;64(12):1925-1931. doi: 10.2967/jnumed.123.266125. J Nucl Med. 2023. PMID: 37827838 Free PMC article.
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
Fizazi K, Shore ND, Smith M, Ramos R, Jones R, Niegisch G, Vjaters E, Wang Y, Srinivasan S, Sarapohja T, Verholen F. Fizazi K, et al. Among authors: verholen f. Eur J Cancer. 2023 Oct;192:113258. doi: 10.1016/j.ejca.2023.113258. Epub 2023 Jul 27. Eur J Cancer. 2023. PMID: 37660438 Free article. Clinical Trial.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Tombal B, Nordquist L, Cookson M, Verholen F, Jhaveri J, Srinivasan S, Smith MR. Shore ND, et al. Among authors: verholen f. Oncologist. 2024 Mar 4;29(3):235-243. doi: 10.1093/oncolo/oyad254. Oncologist. 2024. PMID: 37812679 Free PMC article.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Shore ND, et al. Among authors: verholen f. Oncologist. 2024 Jul 5;29(7):581-588. doi: 10.1093/oncolo/oyae019. Oncologist. 2024. PMID: 38394384 Free PMC article. Clinical Trial.
Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.
O'Sullivan JM, McKay RR, Rahbar K, Fizazi K, George DJ, Tombal B, Schmall A, Sandström P, Verholen F, Shore N. O'Sullivan JM, et al. Among authors: verholen f. Front Med (Lausanne). 2022 Dec 22;9:fmed-09-1070392. doi: 10.3389/fmed.2022.1070392. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36619649 Free PMC article. Review.
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
Higano CS, Dizdarevic S, Logue J, Richardson T, George S, de Jong I, Tomaszewski JJ, Saad F, Miller K, Meltzer J, Sandström P, Verholen F, Tombal B, Sartor O. Higano CS, et al. Among authors: verholen f. Cancer. 2024 Jun 1;130(11):1930-1939. doi: 10.1002/cncr.35221. Epub 2024 Feb 10. Cancer. 2024. PMID: 38340349
Comment on the Safety of Enterococcus faecium SF68.
Verholen F, Schori B, Haering G. Verholen F, et al. J Pediatr Gastroenterol Nutr. 2016 Jan;62(1):e12. doi: 10.1097/MPG.0000000000000937. J Pediatr Gastroenterol Nutr. 2016. PMID: 26252925 No abstract available.
23 results